NCT Number: NCT00302640
Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children
The purpose of this study is to determine the effect of nitazoxanide suspension in treating diarrhea caused by enteric viruses in children less than 12 years of age.
Looking for future studies?
Notify MeKey information
Conditions
Age range
Up to 11 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2 / Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age <12 years.
- Patients with diarrhea (defined as 3 or more stools per day with liquid or semi-solid consistency, the number and consistency of stools being unusual for that person).
- Stool positive for adenovirus, norovirus or rotavirus by ELISA.
Exclusion criteria
- Females who are pregnant, suspected of being pregnant or breastfeeding.
- Other identified causes of diarrhea at screening.
- Serious systemic disorders incompatible with the study.
Treatment and study plan
Primary outcomes
-
Time from first dose to resolution of symptoms.
Time frame: P-0.0105
Median time: 31 hours for nitazoxanide group and 75 hours for the placebo group
Secondary outcomes
-
Virologic response (negative ELISA) at day 7-10.
Sponsors and collaborators
Lead sponsor
Romark Laboratories L.C.
Industry
Registry information
Official study title
Multi-center, Double-blind, Placebo-controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children
Important dates
- Study start
- 2005
- Study completion
- 2005
- First posted
- Mar 14, 2006
- Registry last updated
- May 31, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers
NCT00880698
Blood-Borne Infections, Communicable Diseases
Gaborone, Botswana
View Trial DetailsReactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization
NCT05032391
Infections, RNA Virus Infections
Perm, Russia
View Trial DetailsThis Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
NCT03207750
Infections, RNA Virus Infections
Birmingham, Alabama, United States
View Trial DetailsThe Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity
NCT02992197
Infections, RNA Virus Infections
Dhaka, Bangladesh
View Trial Details